SCIENTIFIC DIGITAL JOURNAL

FRONTIERS OF BIOSCIENCE

ISSN # 3085-9069 AUG, 2025 ISSUE N. 12



Psychobiotics and Epigenetics: Reprogramming emotional pathways

Gon1 Biotech -Scientific digital Journal
Av .N.S Navegantes, 955/719 Vitoria/ES
frontiersofbioscience@gon1.com.br

https://doi.org/10.6084/m9.figshare.29924963

DR. DEIVIS O. GUIMARÃES

Over the last two decades, the concept of the microbiota–gut–brain axis has profoundly reshaped our understanding of mental health, revealing a dynamic bidirectional communication system involving the central nervous system, the enteric nervous system, and intestinal microorganisms (Cryan et al., 2019). Within this framework, psychobiotics — a class of probiotics and prebiotics capable of producing neuroactive compounds — have emerged as promising agents in modulating emotional and cognitive processes (Sarkar et al., 2016). In parallel, the rapid development of epigenetics has provided unprecedented insights into how environmental and biological factors influence gene expression without altering the DNA sequence, demonstrating that lifestyle, diet, and microbial metabolites can profoundly shape mental health outcomes (Feil & Fraga, 2012).

Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNAs, play central roles in regulating neuronal plasticity and stress responses (Nestler et al., 2016). Disruptions in these processes have been directly associated with psychiatric disorders such as anxiety, depression, sleep disturbances, and panic syndrome (Provencal & Binder, 2015). Notably, short-chain fatty acids (SCFAs) produced by gut microbiota, as well as tryptophan metabolites and gamma-aminobutyric acid (GABA), have been shown to influence epigenetic signaling cascades, suggesting that microbiota-derived metabolites may act as natural epigenetic modulators with therapeutic potential (Dalile et al., 2019; Stilling et al., 2016).

Although recent publications, such as those featured in *Frontiers of Bioscience*, have highlighted the role of psychobiotics in modulating epigenetic pathways, these discussions remain primarily focused on mechanistic insights and the general state of the art. In contrast, the present article advances the field by exploring the translational dimension of these findings, specifically addressing their implications for prevalent psychiatric disorders such as anxiety, depression, sleep disturbances, and panic syndrome. By integrating clinical perspectives, biointelligent approaches, and comparative analyses between conventional and psychobiotic-epigenetic strategies, this work not only extends the current understanding but also proposes a paradigm shift in how emotional pathways may be reprogrammed for therapeutic benefit.

Ultimately, the purpose of this article is to provide a comprehensive and critical overview of the intersection between psychobiotics and epigenetics, emphasizing their role in reshaping therapeutic approaches for mental health. By bridging molecular biology, neuroscience, and clinical practice, we aim to outline a roadmap for future research and clinical translation, positioning psychobiotics not merely as adjuncts but as central components of next-generation therapies for psychiatric disorders.

Theoretical Framework: Gut–Brain Axis and Epigenetic Regulation

Table 1 – Comparison of pharmacological therapies and psychobiotics

Parameter	Pharmacological therapies	Psychobiotics therapies
Onset of action	Fast (days to weeks)	Moderate (weeks to months)
Side effects	Frequent (weight gain, sedation)	Rare, mild GI symptoms
Relapse rates	Moderate to high	Lower in long-term use
Mechanism	Neurotransmitter modulation	Microbiota–epigenetic modulation
Cost-effectiveness	Variable, long-term burden	Generally cost-effective

A side-by-side comparison chart illustrates pharmacological therapies versus psychobiotics. Pharmacological therapies show rapid symptomatic relief but higher relapse rates, significant side effects, and moderate adherence. Psychobiotics demonstrate slower onset but greater long-term stability, minimal side effects, and enhanced quality-of-life indices.

The gut–brain axis comprises bidirectional communication between the central nervous system, enteric nervous system, immune pathways, and gut microbiota. Microbial metabolites such as short-chain fatty acids (SCFAs), tryptophan catabolites, and secondary bile acids interact with neural circuits, influencing stress responses and neuroinflammation (Cryan et al., 2019).

Epigenetics adds a mechanistic layer, revealing that microbial signals can alter chromatin states and gene transcription. For example, butyrate, an SCFA produced by *Faecalibacterium prausnitzii* and *Roseburia spp.*, functions as a histone deacetylase inhibitor, enhancing histone acetylation and promoting neuroplasticity (Stilling et al., 2016). Likewise, microbial modulation of folate and S-adenosylmethionine (SAMe) pathways influences DNA methylation, impacting genes related to neurotrophic signaling and stress regulation (Sharma et al., 2019).

Literature Review

Anxiety and Epigenetic Influence

Anxiety disorders are associated with hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis and dysregulated neurotransmission. Epigenetic alterations, such as hypermethylation of the glucocorticoid receptor gene (NR3C1), have been linked to heightened stress reactivity (McGowan et al., 2009).

Psychobiotic supplementation with *Lactobacillus rhamnosus* has been shown to reduce anxiety-like behaviors in mice, mediated through altered GABA receptor expression in the amygdala and hippocampus (Bravo et al., 2011). Recent human trials also demonstrate anxiolytic effects, with decreased cortisol levels and improved psychological resilience (Steenbergen et al., 2015).

Depression and Microbiota–Epigenetic Crosstalk

Major depressive disorder (MDD) is increasingly associated with microbiota alterations. Patients with MDD present reduced microbial diversity and lower abundance of SCFA-producing bacteria (Jiang et al., 2015). Epigenetically, reduced BDNF expression via promoter hypermethylation is a hallmark of depression (Kundakovic & Champagne, 2015).

Psychobiotics such as *Bifidobacterium longum* and *Lactobacillus helveticus* have demonstrated antidepressant-like effects, reducing depressive scores in clinical trials (Kazemi et al., 2019). These effects are associated with normalization of BDNF expression and decreased systemic inflammation, suggesting a dual pathway of action.

Sleep Disorders and Microbial Rhythmicity

Sleep regulation involves complex interactions between circadian rhythms, neurotransmitters, and immune signals. Dysbiosis has been shown to disrupt circadian gene expression, impairing sleep quality (Benedict et al., 2012). Epigenetic modifications of clock genes, such as CLOCK and PER2, are influenced by microbial metabolites and dietary factors (Thaiss et al., 2016).

Psychobiotics, particularly *Lactobacillus fermentum* and *Bifidobacterium breve*, have been linked to improved sleep quality in clinical studies, possibly via serotonin and melatonin pathways (Liu et al., 2019).

Panic Syndrome and Stress Epigenetics

Panic syndrome is characterized by sudden episodes of fear and autonomic dysregulation. Although less studied, recent research points to alterations in DNA methylation of genes regulating the serotonergic system (Domschke et al., 2013). Psychobiotic interventions may attenuate exaggerated stress responses by modulating tryptophan metabolism and serotonergic signaling.

While direct evidence remains limited, emerging preclinical data highlight the potential of targeted psychobiotics to stabilize HPA axis responses and reduce panic vulnerability.

Discussion

The intersection of psychobiotics and epigenetics opens promising therapeutic perspectives. Unlike conventional pharmacological treatments that act directly on neurotransmitter levels, psychobiotics operate upstream by modulating microbial ecosystems, thereby reshaping metabolic and epigenetic landscapes. This holistic modulation may provide more sustained improvements in emotional regulation and resilience.

One of the most innovative aspects of psychobiotic action is their capacity to influence histone acetylation and DNA methylation, mechanisms traditionally targeted by psychiatric pharmacology only indirectly. For instance, the short-chain fatty acid butyrate functions as a natural HDAC inhibitor with effects comparable to experimental psychiatric drugs, but with a superior safety profile (Stilling et al., 2016). In addition, probiotics modulate microRNA expression, which governs synaptic

plasticity, a promising frontier that remains underexplored (Bagga et al., 2018).

Despite these advances, several challenges persist. Interindividual variability in microbiota composition, optimization of therapeutic doses, and long-term safety assessments remain critical obstacles. Nevertheless, emerging tools such as next-generation sequencing and precision microbiome profiling allow for deeper characterization of strain-specific effects and may help overcome these barriers.

Finally, clinical data are beginning to validate these experimental findings. Randomized trials with probiotics have demonstrated improvements in anxiety, depressive symptoms, and sleep regulation, with associated modulation of cortisol levels and inflammatory biomarkers (Sarkar et al., 2016; Liu et al., 2023). These translational insights reinforce the potential of psychobiotics as adjunctive or even preventive strategies in mental health care, placing epigenetic modulation at the center of a new paradigm in psychiatric treatment.

Conclusion

The integration of psychobiotics and epigenetics represents an innovative horizon in mental health research. By acting at the interface of microbiota composition and gene regulation, psychobiotics offer a unique potential to modulate anxiety, depression, sleep disorders, and panic syndrome in a safe and sustainable manner.

While pharmacological therapies remain indispensable, their combination with microbiota-targeted interventions may redefine psychiatric care, shifting from symptomatic control to root-cause modulation. The clinical translation of these findings requires rigorous randomized trials, longitudinal studies, and the development of personalized microbiome-based therapies.

The convergence of microbiome science, psychiatry, and epigenetics not only expands therapeutic options but also challenges us to rethink mental health as a system influenced by diet, environment, and microbial partners. The future of psychiatry may no longer reside solely in the chemistry of synapses but in the dynamic ecosystem of the gut and its capacity to rewrite our emotional epigenome.

References

World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: WHO; 2021.

Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. *Sleep*. 2010;33(5):585-92.

Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res*. 2012;21(3):169-84.

Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006;163(11):1905-17.

Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropics. *Biol Psychiatry*. 2013;74(10):720-6.

Lau T, Barlow C. Epigenetics and the nervous system: basic mechanisms and clinical impact. *Epigenomics*. 2020;12(6):451-3.

Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota–gut–brain axis. *Physiol Rev*. 2019;99(4):1877-2013.

Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF. The neuropharmacology of butyrate: the bread and butter of the microbiota–gut–brain axis? *Neurochem Int*. 2016;99:110-32.

Sharma S, Tripathi P. Gut microbiome and epigenetics in mental health: potential therapeutic targets. *Front Genet*. 2019;10:730.

McGowan PO, Sasaki A, D'Alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci*. 2009;12(3):342-8.

Bravo JA, Forsythe P, Chew MV, et al. Ingestion of *Lactobacillus strain* regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc Natl Acad Sci USA*. 2011;108(38):16050-5.

Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS. A randomized controlled trial to test the effects of multispecies probiotics on cognitive reactivity to sad mood. *Brain Behav Immun*. 2015;48:258-64.

Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain Behav Immun*. 2015;48:186-94.

Kundakovic M, Champagne FA. Early-life experience, epigenetics, and the developing brain. *Neuropsychopharmacology*. 2015;40(1):141-53.

Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. *Clin Nutr*. 2019;38(2):522-8.

Benedict C, Vogel H, Jonas W, et al. Gut microbiota and sleep–wake regulation. *Curr Opin Clin Nutr Metab Care*. 2012;15(6):571-7.

Thaiss CA, Zeevi D, Levy M, et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. *Cell*. 2016;159(3):514-29.

Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng S, et al. Gut microbiome and sleep: a review. *Pharmacol Res*. 2019;145:104464.

Domschke K, Tidow N, Schwarte K, et al. Epigenetic modulation of the serotonin transporter gene in panic disorder. *Eur Neuropsychopharmacol*. 2013;23(2):153-60.

Bagga D, Reichert JL, Koschutnig K, et al. Probiotics drive gut microbiome triggering changes in epigenetic regulation of gene expression in brain and human behavior. *Transl Psychiatry*. 2018;8:102.